Treatment response and several patient-reported outcomes are early determinants of future self-efficacy in rheumatoid arthritis

Michaël Doumen, Diederik De Cock, Sofia Pazmino, Delphine Bertrand, Johan Joly, René Westhovens, Patrick Verschueren, Michaël Doumen, Diederik De Cock, Sofia Pazmino, Delphine Bertrand, Johan Joly, René Westhovens, Patrick Verschueren

Abstract

Background: Self-efficacy, or patients' confidence in their ability to control disease and its consequences, was recently prioritised in EULAR recommendations for inflammatory arthritis self-management strategies. However, it remains unclear which factors influence self-efficacy in early rheumatoid arthritis (RA).

Methods: Data were analysed from the 2-year RCT Care in early RA (CareRA), which studied remission-induction treatment regimens for early RA. Participants completed the Arthritis Self-Efficacy Scale (ASES), Short-Form 36 (SF-36), Revised Illness Perception Questionnaire (IPQ-R), Utrecht Coping List (UCL), RAQoL and Health Assessment Questionnaire (HAQ). Depending on time to first remission (DAS28-CRP < 2.6) and persistence of remission, treatment response was defined as persistent response, secondary failure, delayed response, late response or non-response. The association between ASES scores and clinical/psychosocial factors was explored with Spearman correlation and multivariate linear mixed models. Baseline predictors of week 104 ASES were identified with exploratory linear regression followed by multiple regression of significant predictors adjusted for DAS28-CRP, HAQ, treatment arm, treatment response, cumulative CRP/SJC28 and demographic/serologic confounders.

Results: All 379 patients had a recent diagnosis of RA and were DMARD-naïve at study initiation. Most patients were women (69%) and RF/ACPA-positive (66%), and the mean (SD) age was 52 (13) years. For all tested outcome measures, better perceived health correlated with higher self-efficacy. While patient-reported factors (HAQ, SF-36, RAQoL, IPQ-R, pain, fatigue and patient's global assessment) showed moderate/strong correlations with ASES scores, correlations with physician-reported factors (physician's global assessment, SJC28), TJC28 and DAS28-CRP were weak. Only more favourable outcomes on patient-reported factors and DAS28-CRP were associated with higher ASES scores at each time point. An earlier, persistent treatment response predicted higher ASES scores at both weeks 52 and 104. Significant baseline predictors of week 104 ASES included HAQ; SF-36 mental component score, vitality, mental health and role emotional; IPQ-R illness coherence, treatment control, emotional representations and consequences; UCL Passive reacting; and the RAQoL.

Conclusions: Patient-reported outcomes and treatment response were early determinants of long-term self-efficacy in an early RA trial. These results provide further relevance for the window of opportunity in an early treat-to-target strategy and could help to timely identify patients who might benefit from self-management interventions.

Trial registration: EudraCT 2008-007225-39.

Keywords: Coping; Illness perceptions; Patient-reported outcomes; Predictors; Psychosocial factors; Rheumatoid arthritis; Self-efficacy; Self-management; Window of opportunity.

Conflict of interest statement

The authors declare that they have no competing interests.

© 2021. The Author(s).

Figures

Fig. 1
Fig. 1
Total ASES score at week 52 and week 104, stratified by treatment response profile. Response to treatment was associated with total scores on the Arthritis Self-Efficacy Scale (ASES) at week 52 and week 104, with more favourable responses to treatment resulting in stronger self-efficacy beliefs after both 1 and 2 years of treatment
Fig. 2
Fig. 2
Mediators of the association between treatment response and total ASES score at week 104. Reported are the standardised regression coefficients with indicators of significance (*p < 0.05; **p < 0.01; ***p < 0.001). Treatment response was treated as an ordinal variable with lower values representing earlier and more persistent response. ASES Arthritis Self-Efficacy Scale, SF-36 Short-Form 36, MCS mental component score, IPQ-R Revised Illness Perception Questionnaire, HAQ Health Assessment Questionnaire, PGA patient’s global assessment of disease activity, SJC28 swollen joint count in 28 joints, CRP C-reactive protein

References

    1. Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet. 2016;388(10055):2023–38.
    1. Steunebrink LMM, Oude Voshaar M, Taal E, Vonkeman H, Zijlstra T, van de Laar M. Determinants of perceived health nonimprovement in early rheumatoid arthritis patients with favorable treatment outcomes. Arthritis Care Res. 2018;70(4):510–515.
    1. van der Elst K, Verschueren P, de Cock D, de Groef A, Stouten V, Pazmino S, et al. One in five patients with rapidly and persistently controlled early rheumatoid arthritis report poor well-being after 1 year of treatment. RMD Open. 2020;6(1):e001146.
    1. van der Elst K, Meyfroidt S, de Cock D, de Groef A, Binnard E, Moons P, et al. Unraveling patient-preferred health and treatment outcomes in early rheumatoid arthritis: a longitudinal qualitative study. Arthritis Care Res. 2016;68(9):1278–1287.
    1. Taylor PC, Moore A, Vasilescu R, Alvir J, Tarallo M. A structured literature review of the burden of illness and unmet needs in patients with rheumatoid arthritis: a current perspective. Rheumatol Int. 2016;36:685–695.
    1. Groarke A, Curtis R, Coughlan R, Gsel A. The role of perceived and actual disease status in adjustment to rheumatoid arthritis. Rheumatology (Oxford) 2004;43(9):1142–1149.
    1. Kekow J, Moots R, Khandker R, Melin J, Freundlich B, Singh A. Improvements in patient-reported outcomes, symptoms of depression and anxiety, and their association with clinical remission among patients with moderate-to-severe active early rheumatoid arthritis. Rheumatology (Oxford) 2011;50:401–409.
    1. Matcham F, Davies R, Hotopf M, Hyrich KL, Norton S, Steer S, et al. The relationship between depression and biologic treatment response in rheumatoid arthritis: an analysis of the British Society for Rheumatology biologics register. Rheumatology (Oxford) 2018;57(5):835–843.
    1. Bandura A. Self-efficacy: toward a unifying theory of behavioral change. Psychol Rev. 1977;84(2):191–215.
    1. de Ridder D, Geenen R, Kuijer R, van Middendorp H. Psychological adjustment to chronic disease. Lancet. 2008;372:246–255.
    1. DiRenzo D, Finan P. Self-efficacy and the role of non-pharmacologic treatment strategies to improve pain and affect in arthritis. Curr Treatm Opt Rheumatol. 2019;5:168–178.
    1. Barton JL, Décary S. New galaxies in the universe of shared decision-making and rheumatoid arthritis. Curr Opin Rheumatol. 2020;32(3):273–278.
    1. Van Riel P, Alten R, Combe B, Abdulganieva D, Bousquet P, Courtenay M, et al. Improving inflammatory arthritis management through tighter monitoring of patients and the use of innovative electronic tools. RMD Open. 2016;2(2):1–9.
    1. Nikiphorou E, Santos EJF, Marques A, Böhm P, Bijlsma JWJ, Daien CI, et al. 2021 EULAR recommendations for the implementation of self-management strategies in patients with inflammatory arthritis. Ann Rheum Dis. 2021;80(10):1278–85.
    1. Prothero L, Barley E, Galloway J, Georgopoulou S, Sturt J. The evidence base for psychological interventions for rheumatoid arthritis: a systematic review of reviews. Int J Nurs Stud. 2018;82:20–29.
    1. DiRenzo D, Crespo-Bosque M, Gould N, Finan P, Nanavati J, Bingham CO. Systematic review and meta-analysis: mindfulness-based interventions for rheumatoid arthritis. Curr Rheumatol Rep. 2018;20(12):1–11.
    1. Ndosi M, Johnson D, Young T, Hardware B, Hill J, Hale C, et al. Effects of needs-based patient education on self-efficacy and health outcomes in people with rheumatoid arthritis: a multicentre, single blind, randomised controlled trial. Ann Rheum Dis. 2016;75(6):1126–1132.
    1. Jackson T, Xu T, Jia X. Arthritis self-efficacy beliefs and functioning among osteoarthritis and rheumatoid arthritis patients: a meta-analytic review. Rheumatology (Oxford) 2020;59(5):948–958.
    1. Somers TJ, Shelby RA, Keefe FJ, Godiwala N, Lumley MA, Mosley-Williams A, et al. Disease severity and domain specific arthritis self-efficacy: relationships to pain and functioning in rheumatoid arthritis patients. Arthr Care Res. 2010;62(6):848–856.
    1. Coty MB, Salt EG, Myers JA, Abusalem SK. Factors affecting well-being in adults recently diagnosed with rheumatoid arthritis. J Health Psychol. 2017;22(4):493–504.
    1. Primdahl J, Wagner L, Hørslev-Petersen K. Self-efficacy as an outcome measure and its association with physical disease-related variables in persons with rheumatoid arthritis: a literature review. Musculoskeletal Care. 2011;9(3):125–140.
    1. Hewlett S, Cockshott Z, Almeida C, Richards P, Lowe R, Greenwood R, et al. Sensitivity to change of the rheumatoid arthritis self-efficacy scale (RASE) and predictors of change in self-efficacy. Musculoskeletal Care. 2008;6(1):49–67.
    1. Grønning K, Bratås O, Steinsbekk A. Which factors influence self-efficacy in patients with chronic inflammatory polyarthritis? Musculoskeletal Care. 2016;14(2):77–86.
    1. Stouten V, Westhovens R, Pazmino S, de Cock D, van der Elst K, Joly J, et al. Effectiveness of different combinations of DMARDs and glucocorticoid bridging in early rheumatoid arthritis: two-year results of CareRA. Rheumatology (Oxford) 2019;58(12):2284–2294.
    1. Stouten V, Westhovens R, Pazmino S, de Cock D, van der Elst K, Joly J, et al. Five-year treat-to-target outcomes after methotrexate induction therapy with or without other csDMARDs and temporary glucocorticoids for rheumatoid arthritis in the CareRA trial. Ann Rheum Dis. 2021;0:1–9.
    1. Barlow JH, Williams B, Wright CC. The reliability and validity of the arthritis self-efficacy scale in a UK context. Psychol Health Med. 1997;2(1):3–17.
    1. England B, Sayles H, Mikuls T, Johnson D, Michaud K. Validation of the rheumatic disease comorbidity index. Arthritis Care Res. 2015;67:865–872.
    1. Prevoo M, van’t Hof M, Kuper H, van Leeuwen M, van de Putte L, van Riel P. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995;38:44–48.
    1. Fransen J, Creemers M, van Riel P. Remission in rheumatoid arthritis: agreement of the disease activity score (DAS28) with the ARA preliminary remission criteria. Rheumatology (Oxford) 2004;43:1252–1255.
    1. Bruce B, Fries J. The Stanford health assessment questionnaire: dimensions and practical applications. Health Qual Life Outcomes. 2003;1:20.
    1. Moss-Morris R, Weinman J, Petrie K, Horne R, Cameron L, Buick D. The revised illness perception questionnaire (IPQ-R) Psychol Health. 2002;17:1–16.
    1. Ware JJ, Sherbourne C. The MOS 36-item short-form health survey (SF-36) Med Care. 1992;30:473–483.
    1. De Jong Z, Van Der Heijde D, McKenna SP, Whalley D. The reliability and construct validity of the RAQoL: a rheumatoid arthritis-specific quality of life instrument. Br J Rheumatol. 1997;36(8):878–883.
    1. Schreurs P, Tellegen B, Vanderwillige G. Health, stress and coping - the development of the Utrechtse coping scale. Gedrag-Tijdschr Voor Psychol. 1984;12:101–117.
    1. Smolen JS, Landewé RBM, Bijlsma JWJ, Burmester GR, Dougados M, Kerschbaumer A, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2020;79(6):685–699.
    1. Van Nies JAB, Krabben A, Schoones JW, Huizinga TWJ, Kloppenburg M, Van Der Helm-Van Mil AHM. What is the evidence for the presence of a therapeutic window of opportunity in rheumatoid arthritis? A systematic literature review. Ann Rheum Dis. 2014;73(5):861–870.
    1. van der Elst K, Verschueren P, Stouten V, Pazmino S, de Groef A, de Cock D, et al. Patient-reported outcome data from an early rheumatoid arthritis trial: opportunities for broadening the scope of treating to target. Arthritis Care Res. 2019;71(12):1566–1575.
    1. Barlow JH, Cullen LA, Rowe IF. Educational preferences, psychological well-being and self-efficacy among people with rheumatoid arthritis. Patient Educ Couns. 2002;46(1):11–19.
    1. Schiaffino KM, Revenson TA, Gibofsky A. Assessing the impact of self-efficacy beliefs on adaptation to rheumatoid arthritis. Arthritis Rheum. 1991;4(4):150–157.
    1. Martinez-Calderon J, Meeus M, Struyf F, Luque-Suarez A. The role of self-efficacy in pain intensity, function, psychological factors, health behaviors, and quality of life in people with rheumatoid arthritis: a systematic review. Physiother Theory Pract. 2020;36(1):21–37.
    1. Vergara F, Rosa J, Orozco C, Bertiller E, Gallardo MA, Bravo M, et al. Evaluation of learned helplessness, self-efficacy and disease activity, functional capacity and pain in Argentinian patients with rheumatoid arthritis. Scand J Rheumatol. 2017;46(1):17–21.
    1. Hewlett S, Almeida C, Ambler N, Blair PS, Choy EH, Dures E, et al. Reducing arthritis fatigue impact: two-year randomised controlled trial of cognitive behavioural approaches by rheumatology teams (RAFT) Ann Rheum Dis. 2019;78(4):465–472.

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa